ClinicalTrials.gg
RecruitingNCT06747585Updated Oct 28, 2026

A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

A Phase 1/2 interventional study of ALE.P02 and Pembrolizumab in Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Cervical Squamous Cell Carcinoma, sponsored by Alentis Therapeutics AG. Recruiting at 41 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Alentis Therapeutics AG · Phase 1/2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Oct 28, 2026Site recruiting status changedEnrollment updated+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
235
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain — 36 open to participants now, 70 under way, 14 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Spain.

Planned enrollment
61st of 161
235 · median 160
Started
2024
with 14 others
Phase 1/2
33 of 167
11 open now
Primary completion
2028-02
later than 41 of 69 live
Registered
152nd of 167
by date

Among the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, this one is the 61st largest by planned enrollment of the 161 interventional ones that give a count, is one of 15 that started in 2024, is one of 33 in phase 1/2, reaches primary completion later than 41 of the 69 other live ones, and was the 152nd registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

36 of the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in combination with pembrolizumab in adult patients with selected squamous solid tumors.

Read the detailed description

This Study has a Phase I ALE.P02 monotherapy dose escalation and recommended dose for expansion (RDE) study of ALE.P02 as a monotherapy and combination therapy with pembrolizumab, and a Phase II study of ALE.P02 as a monotherapy at RP2D in adult patients with selected advanced or metastatic Claudin-1 positive (CLDN1+) cancers.

03

Conditions studied

  • Squamous Non-small-cell Lung Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Cervical Squamous Cell Carcinoma
  • Esophageal Squamous Cell Carcinoma

Keywords

  • Claudin-1 Targeted Antibody-Drug Conjugate
  • Monotherapy
  • First-in-Human
  • Recommended Phase 2 dose
  • Recommended dose for expansion
  • Combination therapy
  • Pembrolizumab
  • Anti-PD-1
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have disease and treatment history as: or cytologically confirmed advanced locally recurrent and inoperable or SqNSCLC, HNSCC (nasopharyngeal cancer included), ESCC or CSCC.
  • Phase I Dose Escalation: Have received at least one systemic standard of care regimen and being or intolerant to the treatment.
  • Phase I Monotherapy RDE and Phase II: Have received no more than 2 lines of systemic standard of care regimen and being refractory or intolerant to the treatment.
  • Phase I Combination Therapy RDE: Have received no previous systemic therapy in incurable recurrent or metastatic setting
  • Have provided tissue for CLDN1 analysis in a central laboratory.
  • Have a performance status of 0 or 1 on the Performance Scale.
  • Demonstrate adequate bone marrow and organ function.
  • Patients must have recovered from all toxicities led by prior treatment.
  • Have based on 1.1 as determined by the site.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with cancers of predominantly non-squamous histology (eg, adenosquamous carcinoma) or adenocarcinoma.
  • Has received antineoplastic therapies prior to study intervention within specified time frame.
  • Has rapidly progressing disease (eg, tumor bleeding, uncontrolled tumor pain).
  • Patients with uncontrolled diabetes.
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  • Has gastrointestinal bleeding and has an active infection requiring systemic treatment and has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the clinical study, interfere with the patient's participation for the full duration of the clinical study, or is not in the best interest of the patient to participate.
  • Concomitant use of drugs that are known to prolong or shorten and/or have known risk of Torsades de Pointes.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
235 participants (estimated)

Study arms

  • Experimental
    Phase I Dose Escalation - ALE.P02

    Patients will receive ALE.P02 as monotherapy via intravenous infusion. The ALE.P02 will be given at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined in Phase I dose escalation part of the study.

    Drug: ALE.P02

  • Experimental
    Phase I Dose Expansion - ALE.P02

    Patients will receive ALE.P02 as monotherapy via intravenous infusion. The safe recommended dose of ALE.P02 will be given in Phase I dose expansion part of the study to identify Recommended Phase II Dose (RP2D).

    Drug: ALE.P02

  • Experimental
    Phase II - ALE.P02

    Patients will receive ALE.P02 as monotherapy via intravenous infusion at the RP2D, or according to the dosing schedule after the dose expansion phase.

    Drug: ALE.P02

  • Experimental
    Phase I Dose Escalation - ALE.P02 in combination with pembrolizumab

    Patients will receive ALE.P02 in combination with pembrolizumab via intravenous infusion. The ALE.P02 will be given at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined.

    Drug: ALE.P02 · Drug: Pembrolizumab

  • Experimental
    Phase I Dose Expansion - ALE.P02 in combination with pembrolizumab

    Patients will receive ALE.P02 in combination with pembrolizumab via intravenous infusion. The safe recommended dose of ALE.P02 will be given in Phase I dose expansion part of the study.

    Drug: ALE.P02 · Drug: Pembrolizumab

Interventions

  • DrugALE.P02

    ALE.P02 will be administered by IV infusion according to the assigned arms.

  • Pembrolizumab will be administered per local labeling or institutional guidelines.

06

What researchers measure

Primary outcomes

  1. Number of Patients with Dose Limiting Toxicities (DLTs)

    DLTs as defined in the protocol will be assessed to evaluate safety and tolerability of ALE.P02 as a monotherapy or in combination with pembrolizumab (Phase I Dose Escalation), and to establish RP2D for ALE.P02 (Phase I RDE).

    Time frame: Up to 28 days

  2. Number of Patients with Adverse Events

    Adverse events will be assessed to evaluate safety and tolerability of ALE.P02 as a monotherapy or in combination with pembrolizumab (Phase I Dose Escalation), and to establish RP2D for ALE.P02 (Phase I RDE).

    Time frame: Screening (day -28 to day -1) up to Safety follow-up (30 ± 5 days post last dose [Up to 3.5 years])

  3. Overall Response Rate (ORR) (Phase I)

    The ORR is the proportion of patients with a best overall response (BOR) of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.) This is assessed to establish RP2D for ALE.P02 (Phase I RDE)

    Time frame: From ALE.P02 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 3.5 years)

  4. Duration of Response (DoR) (Phase I)

    The DoR is defined for patients achieving a confirmed CR or PR as the time from the initial response of CR or PR per Investigator review according to RECIST 1.1 to disease progression or death of any cause, whichever occurs earlier. This is assessed to establish RP2D for ALE.P02 (Phase I RDE).

    Time frame: From ALE.P02 treatment initiation until disease progression or study completion (Up to 3.5 years)

  5. Overall Response Rate (ORR) (Phase II)

    The ORR is assessed to assess evaluate anti-tumor activity of ALE.P02 as a monotherapy (Phase II).

    Time frame: From ALE.P02 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 3.5 years)

  6. Duration of Response (DoR) (Phase II)

    The DoR is assessed to evaluate assess anti-tumor activity of ALE.P02 as a monotherapy (Phase II).

    Time frame: From ALE.P02 treatment initiation until disease progression or study completion (Up to 3.5 years)

Secondary outcomes

  1. Disease control rate (DCR) (Phase I and II)

    The DCR is defined as the proportion of patients with a confirmed BOR of CR or PR or stable disease (SD) per Investigator review according to RECIST 1.1 at or prior to initiation of the use of new anti-cancer therapy. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P02 (Phase I and II).

    Time frame: From ALE.P02 treatment initiation until at or prior to initiation of the use of new anti-cancer therapy (Up to 3.5 years)

  2. Median Progression-Free Survival (PFS) at 6 and 12 Months (Phase I and II)

    The PFS is defined as time from first study treatment to a documented disease progression according to RECIST 1.1, as determined by the Investigator, or death due to any cause, whichever occurs earlier. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P02 (Phase I and II).

    Time frame: At 6 and 12 months after initiation of ALE.P02 treatment

  3. Median Overall Survival (OS) at 6, 12, and 24 Months (Phase I and II)

    The OS is defined as time from first study treatment to death due to any cause. This is assessed to evaluate preliminary evidence of anti-tumor activity of ALE.P02 (Phase I and II).

    Time frame: At 6, 12, and 24 months after initiation of ALE.P02 treatment

  4. Blood Concentration of ALE.P02 Antibody-drug Conjugate (ADC)

    Concentrations of ALE.P02 ADC in blood will be measured at each scheduled time point per arms to assess the pharmacokinetic (PK) profile of ALE.P02.

    Time frame: Phase I and II: Cycle 1 Day 1 until at end of treatment visit (EoT) (Up to 3.5 years)

  5. Blood Concentration of Total Antibody

    Total antibody in blood will be measured at each scheduled time point per arms to assess the PK profile of ALE.P02.

    Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)

  6. Blood Concentrations of Payload

    Concentrations of payload in blood will be measured at each scheduled time point per arms to assess the PK profile of ALE.P02.

    Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)

  7. Area under the concentration-time curve over the dosing interval (AUCtau)

    The AUCtau of ALE.P02 will be measured to assess the pharmacokinetic (PK) profile of ALE.P02.

    Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)

  8. Area under the concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (AUClast)

    The AUClast of ALE.P02 will be measured to assess the PK profile of ALE.P02.

    Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)

  9. Area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time (AUCinf)

    The AUCinf of ALE.P02 will be measured to assess the PK profile of ALE.P02.

    Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)

  10. Maximum Concentration (Cmax)

    The Cmax of ALE.P02 will be measured to assess the PK profile of ALE.P02. It is determined directly from the concentration-time profile.

    Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)

  11. Minimum concentration (Cmin)

    The Cmin of ALE.P02 will be measured to assess the PK profile of ALE.P02. It is determined directly from the concentration-time profile.

    Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)

  12. Concentration at the end of a Dosing Interval (Ctrough)

    The Ctrough of ALE.P02 will be measured to assess the PK profile of ALE.P02.

    Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)

  13. The terminal elimination rate constant (KeL)

    The KeL of ALE.P02 will be measured to assess the PK profile of ALE.P02. It is determined by selection of at least three data points on the terminal phase of the concentration-time curve.

    Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)

  14. Terminal elimination half-life (t½)

    The t½ of ALE.P02 will be measured to assess the PK profile of ALE.P02.

    Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)

  15. Time of Maximum Concentration (tmax)

    The tmax of ALE.P02 will be measured to assess the PK profile of ALE.P02.

    Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)

  16. Average Concentration (Cavg)

    The Cavg of ALE.P02 will be measured to assess the PK profile of ALE.P02.

    Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)

  17. Number of Patients with Presence of anti-ALE.P02 Antibodies

    Presence of anti-ALE.P02 Antibodies will be assessed to evaluate the immunogenicity of ALE.P02.

    Time frame: Phase I and II: Cycle 1 Day 1 until at EoT (Up to 3.5 years)

07

Study locations

39 of 41 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Feb 2028, 37 months after the start.

Of 92 industry-sponsored phase 1/2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's planned 37 months is below that.

Counting every sponsor, half of 137 studies reached it within 61 months; a quarter within 47 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 24, 2024
StartActual
Dec 16, 2024
Primary completionEst.
Feb 15, 2028
CompletionEst.
Aug 15, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now withdrawn)
Show 2 sites
  • Yale Comprehensive Cancer Center · New Haven, United StatesRecruiting→Withdrawn
  • Norton Cancer Institue Downtown · Louisville, United StatesRecruiting→Withdrawn
Oct 28, 2026
Enrollment
170→235
Oct 28, 2026
Eligibility
2 inclusion criteria edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedHave disease and treatment history as: Have histologically or cytologically confirmed advanced locally recurrent and inoperable or metastatic SqNSCLC, HNSCC (nasopharyngeal cancer included), ESCC or CSCC.
  • EditedPhase I Monotherapy RDE and Phase II: Have received no more than 2 lines of systemic standard of care regimen and being refractory or intolerant to the treatment.
  • AddedPhase I Combination Therapy RDE: Have received no previous systemic therapy in incurable recurrent or metastatic setting
Oct 28, 2026
Interventions
Added Drug: Pembrolizumab. Arms added: Phase I Dose Escalation - ALE.P02 in combination with pembrolizumab·Phase I Dose Expansion - ALE.P02 in combination with pembrolizumab
Oct 28, 2026
Primary outcomes
4 description edited
What changed in the outcomes
  • DescriptionDuration of Response (DoR) (Phase II): how it is measured was reworded
  • DescriptionNumber of Patients with Adverse Events: how it is measured was reworded
  • DescriptionNumber of Patients with Dose Limiting Toxicities (DLTs): how it is measured was reworded
  • DescriptionOverall Response Rate (ORR) (Phase II): how it is measured was reworded
Oct 28, 2026
Title
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    2 sites changed recruiting status (2 now withdrawn)
    Show 2 sites
    • Yale Comprehensive Cancer Center · New Haven, United StatesRecruiting→Withdrawn
    • Norton Cancer Institue Downtown · Louisville, United StatesRecruiting→Withdrawn
    Enrollment 170→235
    Eligibility 2 inclusion criteria edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedHave disease and treatment history as: Have histologically or cytologically confirmed advanced locally recurrent and inoperable or metastatic SqNSCLC, HNSCC (nasopharyngeal cancer included), ESCC or CSCC.
    • EditedPhase I Monotherapy RDE and Phase II: Have received no more than 2 lines of systemic standard of care regimen and being refractory or intolerant to the treatment.
    • AddedPhase I Combination Therapy RDE: Have received no previous systemic therapy in incurable recurrent or metastatic setting
    Primary outcomes 4 description edited
    What changed in the outcomes
    • DescriptionDuration of Response (DoR) (Phase II): how it is measured was reworded
    • DescriptionNumber of Patients with Adverse Events: how it is measured was reworded
    • DescriptionNumber of Patients with Dose Limiting Toxicities (DLTs): how it is measured was reworded
    • DescriptionOverall Response Rate (ORR) (Phase II): how it is measured was reworded
    Interventions Added Drug: Pembrolizumab. Arms added: Phase I Dose Escalation - ALE.P02 in combination with pembrolizumab·Phase I Dose Expansion - ALE.P02 in combination with pembrolizumab
    Title A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06747585
Lead sponsor
Alentis Therapeutics AG
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Dec 16, 2024
Primary completion
Feb 15, 2028 (estimated)
Completion
Aug 15, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Alentis Clinical Trial Contact
Contact
patientinfo@alentis.ch
+41782304288

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion